Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology
暂无分享,去创建一个
G. Filippatos | M. Metra | P. Seferovic | G. Rosano | S. Adamopoulos | A. Coats | D. Miličić | M. Masetti | T. Thum | M. Crespo-Leiro | L. Hill | K. Damman | F. Gustafsson | L. Tops | N. Jonge | S. Nalbantgil | M. Bonios | T. Ben Gal | J. Parissis | D. Kaye | E. Jankowska | M. Mehra | L. V. van Laake
[1] C. Uzoigwe,et al. Genetically Modified Porcine-to-Human Cardiac Xenotransplantation. , 2022, The New England journal of medicine.
[2] A. Cohen-Solal,et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. , 2022, JAMA.
[3] K. Anstrom,et al. Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. , 2022, JACC. Heart failure.
[4] S. Solomon,et al. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial , 2022, European heart journal.
[5] N. Mewton,et al. Practical outpatient management of worsening chronic heart failure , 2022, European journal of heart failure.
[6] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[7] M. Ochiai,et al. The use of peripherally inserted central catheter reduced the incidence of phlebitis in heart failure patients: A randomized trial. , 2021, The journal of vascular access.
[8] K. Anstrom,et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2021, JAMA cardiology.
[9] M. Martínez‐Sellés,et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study , 2021, ESC heart failure.
[10] S. Solomon,et al. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. , 2021, JAMA cardiology.
[11] David R. Liu,et al. In vivo somatic cell base editing and prime editing. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] K. Khush,et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report - 2021; Focus on recipient characteristics. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] J. Teerlink,et al. Inotropic therapies in heart failure and cardiogenic shock: an educational review. , 2021, European heart journal. Acute cardiovascular care.
[14] M. Metra,et al. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? , 2021, European heart journal. Cardiovascular pharmacotherapy.
[15] Jose H. Flores-Arredondo,et al. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. , 2021, Journal of the American College of Cardiology.
[16] P. Ponikowski,et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.
[17] S. Solomon,et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study , 2020, European heart journal.
[18] F. Rutten,et al. Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper , 2020, European journal of heart failure.
[19] G. Filippatos,et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.
[20] R. M. Masterson Creber,et al. The Development and Implementation of a Cardiac Home Hospice Program: Results of a RE-AIM Analysis , 2020, The American journal of hospice & palliative care.
[21] E. Wolf,et al. Pig-to-non-human primate heart transplantation: The final step toward clinical xenotransplantation? , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[22] Leway Chen,et al. Long-term milrinone therapy as a bridge to heart transplantation: Safety, efficacy, and predictors of failure. , 2020, International journal of cardiology.
[23] G. Filippatos,et al. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo‐controlled trial , 2020, European journal of heart failure.
[24] S. Ricksten,et al. Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. , 2020, Journal of critical care.
[25] J. Alpert,et al. Safety of Outpatient Milrinone Infusion in End Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. , 2019, The American journal of medicine.
[26] A. Mebazaa,et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. , 2019, International journal of cardiology.
[27] A. Mebazaa,et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper , 2019, Critical Care.
[28] K. Rossing,et al. Relationship between invasive hemodynamics and liver function in advanced heart failure , 2019, Scandinavian Cardiovascular Journal.
[29] L. Allen,et al. Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[30] L. Stevenson,et al. Trends in Utilization and Outcomes of Pulmonary Artery Catheterization in Heart Failure With and Without Cardiogenic Shock. , 2019, Journal of cardiac failure.
[31] Fabio Bernini,et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs , 2019, Nature.
[32] Cinzia Perrino,et al. ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure , 2019, Cardiovascular research.
[33] M. Garry,et al. Interspecies Chimeras and the Generation of Humanized Organs. , 2019, Circulation research.
[34] G. Filippatos,et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.
[35] F. Fedele,et al. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post‐discharge period , 2018, ESC heart failure.
[36] P. Ponikowski,et al. Treatments targeting inotropy. , 2018, European heart journal.
[37] D. Kass,et al. Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial. , 2018, JACC. Heart failure.
[38] D. Kaye,et al. Extended Release Oral Milrinone, CRD-102, for Advanced Heart Failure. , 2018, The American journal of cardiology.
[39] L. Allen,et al. Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis. , 2018, JACC. Heart failure.
[40] M. Morshuis,et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry , 2018, European heart journal.
[41] E. Bollano,et al. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial , 2018, Journal of the American Heart Association.
[42] Davor Milicic,et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.
[43] M. Grau,et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION‐HEART multicentre randomised trial , 2018, European journal of heart failure.
[44] D. Burkhoff,et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. , 2018, JACC. Heart failure.
[45] Shunichi Homma,et al. Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells , 2018, Nature Biomedical Engineering.
[46] J. Vercammen,et al. Effects of intravenous home dobutamine in palliative end‐stage heart failure on quality of life, heart failure hospitalization, and cost expenditure , 2018, ESC heart failure.
[47] M. Kittleson,et al. Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond , 2017, Current Heart Failure Reports.
[48] F. Fedele,et al. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. , 2017, International journal of cardiology.
[49] G. Malfatto,et al. Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications , 2017, Journal of cardiovascular pharmacology.
[50] K. Poss,et al. Cardiac regeneration strategies: Staying young at heart , 2017, Science.
[51] E. Agricola,et al. Effects of functional tricuspid regurgitation on renal function and long-term prognosis in patients with heart failure , 2017, Journal of cardiovascular medicine.
[52] J. Muldowney,et al. A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure , 2016, JACC. Basic to translational science.
[53] L. V. Van Laake,et al. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. , 2016, European heart journal.
[54] Amit N. Patel,et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. , 2016, JAMA cardiology.
[55] Akshay S. Desai,et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial , 2016, The Lancet.
[56] C. Morgan,et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure , 2015, Circulation. Heart failure.
[57] Amit N. Patel,et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial , 2015, European heart journal.
[58] H. Ulmer,et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial , 2014, European journal of heart failure.
[59] H. Ke,et al. Advances in targeting cyclic nucleotide phosphodiesterases , 2014, Nature Reviews Drug Discovery.
[60] R. V. van Domburg,et al. Weaning from inotropic support and concomitant beta‐blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis , 2014, European journal of heart failure.
[61] G. Steinbeck,et al. Preconditioning with levosimendan before implantation of left ventricular assist devices. , 2014, Artificial organs.
[62] G. Filippatos,et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. , 2014, International journal of cardiology.
[63] F. Fedele,et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms , 2014, European journal of heart failure.
[64] Adrian F Hernandez,et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.
[65] R. Gramling,et al. “That Don’t Work for Me”: Patients’ and Family Members’ Perspectives on Palliative Care and Hospice in Late-Stage Heart Failure , 2013, Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association.
[66] B. Massie,et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.
[67] M. Taitel,et al. Place of Death Among Patients With Terminal Heart Failure in a Continuous Inotropic Infusion Program , 2012, The American journal of hospice & palliative care.
[68] J. Cleland,et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.
[69] J. Goldman,et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study , 2011, The Lancet.
[70] L. Deliens,et al. Involvement of palliative care services strongly predicts place of death in Belgium. , 2010, Journal of palliative medicine.
[71] J. Vincent,et al. Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.
[72] D. DeMets,et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials , 2009, European heart journal.
[73] P. Ponikowski,et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.
[74] A. Cohen-Solal,et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β‐blockers in SURVIVE † , 2009, European journal of heart failure.
[75] G. Navis,et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. , 2009, Journal of the American College of Cardiology.
[76] M. Loebe,et al. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. , 2008, Journal of Cardiac Failure.
[77] P. Pentikäinen,et al. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[78] A. Cohen-Solal,et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.
[79] Stephanie Läer,et al. Carvedilol but Not Metoprolol Reduces β-Adrenergic Responsiveness After Complete Elimination From Plasma In Vivo , 2004, Circulation.
[80] Christopher M O'Connor,et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.
[81] M. Metra,et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. , 2002, Journal of the American College of Cardiology.
[82] N. Freemantle,et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.
[83] J. Cleland,et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.
[84] R. Califf,et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.
[85] J. Hegbrant,et al. Dose Regimen Adjustment for Milrinone in Congestive Heart Failure Patients with Moderate and Severe Renal Failure , 1995, The Journal of pharmacy and pharmacology.
[86] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.
[87] D. Kaye,et al. Extended Release Oral Milrinone for the Treatment of Heart Failure with Preserved Ejection Fraction , 2019, Heart, Lung and Circulation.
[88] M. Hannan,et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[89] J. Papp,et al. STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .